Use of ophthalmic medications in pregnant and nursing women.
D000318:Adrenergic beta-Agonists / Q000009:adverse effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D001942:Breast Feeding; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D019793:Fluorescein; D005452:Fluoresceins / Q000493:pharmacokinetics; D006801:Humans; D008916:Miotics / Q000009:adverse effects; D009184:Mydriatics / Q000009:adverse effects; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D011247:Pregnancy / Q000187:drug effects*; D051381:Rats
D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D002257:Carbonic Anhydrase Inhibitors; D005452:Fluoresceins; D008916:Miotics; D009184:Mydriatics; D009883:Ophthalmic Solutions; D019793:Fluorescein